39 results about "Cochlea" patented technology

The invention discloses a pharmaceutical composition and application thereof in preparation of a medicine for treating sudden deafness, pharmacodynamic data shows that all components of the composition have a synergistic effect, the solubility and bioavailability of the composition in water can be remarkably improved, and the pharmaceutical composition can be used for treating sudden deafness. Through an oral administration mode, the hearing threshold of cochlear ischemia reperfusion model animals can be remarkably reduced, release of inflammatory factors such as serum IL-1beta and TNF-alpha is inhibited, oxidative stress is relieved (the malondialdehyde level is reduced), so that multi-target synergistic treatment of sudden deafness is realized, the effect is remarkable, the defects that an existing drug is single in target and inconvenient to administrate are overcome, and the application prospect is wide. The important clinical application value is realized.

To provide a system for diagnosing cochlear hydrops of a person or an animal.SOLUTION: The system comprises an acoustic stimulus generating unit comprising a stimulus generator and an output transducer, where the acoustic stimulus generating unit is configured to provide an audio stimulus by the stimulus generator to at least one of ears of a person or animal via the output transducer, wherein the acoustic stimulus generating unit is configured to provide a plurality of audio stimuli comprising at least a first click audio stimulus and at least a first chirp audio stimulus, or at least a first and a second chirp audio stimuli, a recording unit configured to record one or more auditory electrophysiological response of the person or animal in response to one or more audio stimuli being provided by the acoustic stimulus generating unit to at least one of the ears of the person or animal, and a diagnostic unit configured to process a recorded ABR.SELECTED DRAWING: Figure 1

The invention discloses a curcumin-loaded targeted cell membrane derived vesicle delivery system and application thereof, and belongs to the field of biological medicine. The invention relates to a curcumin-loaded targeted cell membrane derived vesicle delivery system, which comprises a cell membrane vesicle; the IETP2 ear-targeted polypeptide is modified on the surface of the cell membrane vesicle; and the curcumin is encapsulated in the cell membrane vesicles. Compared with the prior art, the curcumin has the advantages that the curcumin is systematically illuminated for the first time to improve the mitochondrial function and inhibit oxidative stress and apoptosis to prevent and treat the drug-induced deafness by regulating cAMP / PKA / CREB pathways; the cell membrane derived vesicles modified by the IETP2 polypeptide are used as a targeted delivery system of curcumin, and accumulation of drugs in cochlea is remarkably improved; an animal model verifies that the delivery system has a stronger hearing protection effect and better biological safety compared with free curcumin.

The present application relates to a system for diagnosing cochlear hydrops of a person or an animal. The system comprises an acoustic stimulus generating unit comprising a stimulus generator and an output transducer, where the acoustic stimulus generating unit is configured to provide an audio stimulus by the stimulus generator to at least one of the ears of the person or animal via the output transducer, wherein the acoustic stimulus generating unit is configured to provide a plurality of audio stimuli comprising at least a first click audio stimulus and a first chirp audio stimulus or at least a first and a second chirp audio stimuli, a recording unit configured to record one or more auditory electrophysiological response of the person or animal in response to the one or more audio stimulus being provided by the acoustic stimulus generating unit to at least one of the ears of the person or animal, and a diagnostic unit configured to process the recorded ABR.

The invention relates to a single-source-domain generalization motor fault diagnosis method, system and device based on cochlea perception enhancement and parameter space integration and a medium, and the method comprises the steps: carrying out the multiband modal decomposition of an original vibration signal, and generating a two-dimensional time-frequency image through the combination of Mel frequency mapping; disturbance is applied to a frequency domain amplitude spectrum of the two-dimensional time-frequency image, a phase spectrum is kept unchanged, and an enhanced image is generated through time domain reconstruction and dynamic range normalization; constructing a fault diagnosis model, inputting the two-dimensional time-frequency image into a main branch for fault feature modeling, and inputting an enhanced image into an auxiliary branch to learn potential features so as to update parameters of the auxiliary branch; parameters of the auxiliary branch are obtained through periodic snapshot sampling and fused to the main branch to form a fault diagnosis model. The robustness and generalization ability of a single-source domain fault diagnosis model are improved through the synergistic effect of signal representation optimization inspired by biological perception, physical consistency disturbance enhancement and a double-branch progressive knowledge fusion mechanism.

According to one embodiment, a method, computer system, and computer program product for performing in-situ stimulation adjustments of a cochlear implant. The embodiment may include identifying, dynamically, a first set of magnetic coils and a second set of magnetic coils based on dominant frequency components of a received sound. The first set and the second set are implanted within a cochlea of a user having a cochlear implant (CI). The embodiment may include activating, according to a stimulator profile of the user, the first set via an electric current sent to the first set in order to stimulate cochlear neurons. The embodiment may include determining that an in-situ adjustment to the activation of the first set is required based on analysis of a cochlear neuronal response recorded via the second set. The embodiment may include adjusting the stimulator profile.

The invention discloses a method for separating cochlea related cells in situ based on a patch clamp system. The method comprises the following steps: contacting an electrode with a target single cell under a microscope, and carrying out in-situ grabbing on the target single cell through negative pressure adsorption; the target single cell and surrounding cells are kept in a connection state before in-situ grabbing; before the electrode approaches the target single cell, positive pressure is continuously applied, and when the electrode is in contact with the surface of the target single cell, the positive pressure is instantly stopped and switched to negative pressure. According to the method provided by the invention, high-quality cochlea related cells can be obtained in situ for deep sequencing analysis, and the method can be used for basic research and accurate diagnosis and treatment of clinical hearing impairment, and has a good application prospect.

Provided is an expression cassette for expressing GJB2 protein, which comprises a cochlear supporting cell and cochlear lateral wall-specific promoter and a nucleic acid encoding GJB2 protein. Also provided is a recombinant adeno-associated viral vector, the genome of which comprises an expression cassette for expressing GJB2 protein inserted between two ITR sequences; and a combination of at least two recombinant adeno-associated viral vectors. The recombinant adeno-associated viral vector or combination thereof can be used for treating or preventing hearing loss associated with defects in the GJB2 gene.

The invention relates to the technical field of gene engineering, in particular to a Cilp gene enhancer and application thereof. Through integration and verification of an ATAC-seq map, a single cell transcriptome data set and multi-omics data, the Cilp gene enhancer is obtained through screening, and a mouse inner ear microinjection system is utilized to further prove that the Cilp gene enhancer can significantly enhance the transcriptional activity of an EGFP protein gene in cochlea type 2 neuronal cells. Compared with other sequences with similar sizes, the Cilp gene enhancer provided by the invention can drive specific expression of a reporter gene or a Cilp gene in cochlear neurons, especially type 2 neurons, and the gene expression level is remarkably improved. The Cilp gene enhancer provided by the invention is suitable for biological materials such as recombinant DNA (deoxyribonucleic acid), vectors or adenoviruses, can be used for promoting transcription of EGFP (enhanced green fluorescent protein) genes or other genes in cochlea neurons, and provides a new targeting tool for gene therapy of hereditary hearing loss.

1. The name of the design product: ear mold for fixing cochlea. 2. The use of the design product: ear mold for fixing cochlea. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

The utility model relates to a scalp pressure detection device for an artificial cochlea sound processor. The scalp pressure detection device comprises a sound processor positioning plate, an implant fixing plate and a pressure detection assembly, the implant fixing plate is used for placing an implant; the sound processor positioning plate is placed above the implant fixing plate, a cavity matched with the sound processor in shape is formed in the sound processor positioning plate and used for clamping and fixing the sound processor, the surface of the cavity is coated with a buffer material, and a base plate is arranged between the cavity and the implant fixing plate; the pressure detection assembly comprises a lifting device and a tension dial gauge, one end of the lifting device is connected with the tension dial gauge, the other end of the lifting device is connected with the sound processor positioning plate, and the lifting device is used for applying tension far away from the implant fixing plate to the sound processor positioning plate; the tension dial gauge is used for reading the value of the tension applied by the lifting device when the two are completely separated. Compared with the prior art, the device structure can be simplified and the detection efficiency can be improved while product damage caused by detection can be avoided.

The present invention relates to an elongate passive drug delivery device (10) which is introduced into the cochlea of a patient's ear. The invention relates to a passive drug delivery device (10) extending along a fluid delivery axis X and comprising a fluid conduit (12) having three portions (12a, 12b, 12c) arranged along the fluid delivery axis X, each portion (12a, 12b, 12c) exhibiting an inner diameter (DI1, DI2) and an outer diameter (DO1, DO2, DO3):-an upstream portion (12a) having a first inner diameter (DI1) and a first outer diameter (DO1),-an intermediate portion (12b) having a second inner diameter (DI2) and a second outer diameter (DO2), -a downstream portion (12c) configured to be introduced into the ear (100) of the patient and having a third inner diameter (DI3) and a third outer diameter (DO3), the first inner diameter (DI1) being smaller than the third inner diameter (DI3) and the first outer diameter (DO1) being greater than or equal to the third outer diameter (DO3).

The invention provides a neuromorphic auditory sense processing system and auditory sense sensing equipment based on a sensing and calculation integrated framework. According to the system, a whole processing task is divided into a processing system PS end and a programmable logic PL end; the ARM kernel located at the PS end of the processing system is responsible for advanced task scheduling and external storage control, and all high-load neuromorphic processing tasks are unloaded to the PL end; the PL end serves as a core computing unit and integrates a parallel bionic cochlea model and a pulse neural network engine; the parallel bionic cochlea model communicates with the pulse neural network engine through a high-speed AXI-Stream bus, and seamless transmission of a pulse event flow between a sensing front end and a calculation rear end is ensured. According to the method, through simulating a complete process of a biological auditory path, efficient integration from original audio perception to pulse feature extraction to classification decision is realized.

The present application discloses determining cochlear fluid based on recorded electro-physiological responses, wherein a system for diagnosing cochlear fluid in a human or animal comprises: an acoustic stimulus generation unit comprising a stimulus generator and an output transducer, wherein the acoustic stimulus generation unit is configured to provide an audio stimulus to at least one ear of the human or animal via the output transducer by means of the stimulus generator, wherein the acoustic stimulus generation unit is configured to provide a plurality of audio stimuli comprising at least a first click audio stimulus and a first chirp audio stimulus or comprising at least a first and a second chirp audio stimulus; a recording unit configured to record one or more electro-physiological responses of the human or animal in response to one or more audio stimuli provided to at least one ear of the human or animal by means of the acoustic stimulus generation unit; and a diagnostic unit configured to process the recorded electro-physiological responses.

Implant electrode insertion system (1) for inserting an implant electrode into the cochlea (99), comprising an oct device (2) comprising an oct probe (3) defining an optical axis (A) and configured to be held in a measurement position outside of the cochlea and configured to provide an orientation signal representative for an orientation of the oct probe with respect to a cochlea, measured using optical coherence tomography of light emitted from the probe in the measurement position along the optical axis (A); an implant electrode insertion module (4) connected to the oct device, and configured to be arranged in an insertion position on the basis of the orientation signal; and an alignment unit (5) configured to assist in positioning of the implant electrode insertion module (4) in the insertion position on the basis of the orientation signal; wherein the implant electrode insertion module (4) comprises an electrode guide that defines a guide axis (G), and is configured to, in the insertion position, guide a cochlear implant electrode along the guide axis towards the cochlea, wherein the guide axis (G) is coaxial with the optical axis (A) of the oct device.

The present disclosure relates to an implantable stimulation assembly. An elongate stimulation assembly of an implantable stimulation device includes an intra-cochlear portion including an electrode array, and an extra-cochlear portion extending from the intra-cochlear portion, where the extra-cochlear portion includes a plurality of electrical leads in electrical communication with the electrode array, and an extendable member extending in an elongate manner, where the plurality of electrical leads are in electrical communication with the electrode array. The extendable member is positioned at a further distance from the longitudinal axis of the extracochlear portion than at least one of the plurality of electrical lead wires.

The present invention provides a cochlear and / or vestibular cell-specific promoter and use thereof, and specifically relates to specific promoters STRC, Slc26a5, otof, Sox10, Ngfr1, Ngfr2, and Dnah5 and use thereof in cochlear and / or vestibular cells. The nucleotide sequences of the specific promoters are as set forth in SEQ ID NOs. 1, 6, 11, 16, 21, 26, and 31, respectively. Also provided is a recombinant vector comprising the specific promoters. On the basis of the fact that the promoters are characterized by specific expression in cochlea and / or vestibule, use of the tissue-specific promoters, an amplification primer, the recombinant vector, or a pharmaceutical composition in gene therapies, construction of related animal models, pathogenesis-related researches, and the like for hearing-related diseases is provided.

The invention relates to a test to measure the ability of a subject to discriminate between speech sounds. The speech sounds may be selected from the world's most widely spoken languages to enable the test to be carried out irrespective of the language spoken by the subject. Speech sounds may be presented in sequences, such as triplets. The subject would then be required to detect which speech sound in each sequence is different from the others. The test may be provided on a computer or similar device, in an embodiment a tablet computer, enabling the subject to conduct a self-assessment. The test may be performed on hearing aid users to determine the likelihood of a hearing aid user obtaining better test results after receiving one or two cochlear implants.

A patient-specific method of conditioning a cochlear electrode array so as to reduce insertion forces is provided. The method includes obtaining a 3D phantom of at least a portion of a scala tympani of a patient. The cochlear electrode array is inserted into and removed out of the 3D model of the scala tympani one or more times, to condition (e.g. soften) the electrode prior to insertion into the patient's scala tympani. Trauma when inserting the electrode into the cochlea is thus reduced.

The application belongs to the field of edge speech recognition, and discloses a brain-like edge speech recognition system and method based on neural information coding. The system comprises an audio sampling front end, a cochlea-like auditory encoder, a sparse compression and local wake-up module, and an RRAM in-memory computing core. The audio sampling front end receives environmental sound signals and generates digitized audio data; the cochlea-like auditory encoder generates a sparse spatiotemporal pulse event sequence from the digitized audio data; the sparse compression and local wake-up module compresses the sparse spatiotemporal pulse event sequence and generates wake-up instructions and skip instructions for a subarray in the RRAM in-memory computing core; and the RRAM in-memory computing core activates the subarray to output a speech recognition result according to the wake-up instructions. The application generates sparse pulses by simulating the neural information encoder of a biological cochlea, combines the RRAM in-memory computing core to complete SNN deployment, and realizes sparse pulse compression and local wake-up data flow control, thereby achieving low-power-consumption, low-delay, high-robustness, and high-adaptability edge speech recognition.

When the volute chamber structure is used, the second end of the second shell plate is horizontally connected to the first shell plate in a lap joint mode, a rigid joint supporting each other is structurally formed, a high-rigidity box-like section is jointly formed, the scheme that in the prior art, the structural strength is guaranteed through material stacking is replaced, and after the plate thickness is reduced, the structural strength is improved. The whole volute chamber structure can still keep the non-deformability, the first shell plate is connected in a vertical state, the second shell plate is connected in a horizontal state, and therefore a complex contour is decomposed into two independent components with the clear main direction, thickness and structure optimization can be conducted according to actual stress of all the plates, and on the premise that the strength is met, the overall performance of the volute chamber is improved. Therefore, accurate thinning of the first shell plate and the second shell plate is realized, the material consumption and weight are directly reduced, the overall weight of the shell is further reduced, and lightweight design is realized. The invention further relates to an assembling method.

This proposal presents a speech fundamental frequency detection method and device based on bio-auditory inspiration, comprising: acquiring the speech signal to be detected; constructing multiple frequency channels corresponding to different frequencies within a preset fundamental frequency search range; inputting the speech signal to be detected into each frequency channel; acquiring candidate intervals of periodic structures and corresponding confidence scores of periodic structures in the frequency channels; obtaining the fundamental frequency estimate of the current frame based on the candidate intervals of periodic structures; and performing speech process recognition on the fundamental frequency estimates of multiple consecutive current frames to obtain a continuous speech fundamental frequency trajectory. This scheme employs a biomimetic multi-channel bandpass filter, conforming to the channel-specific processing mechanism of the cochlea, preserving the temporal details of the signal, and marking the 1 / 2 structure evidence of periodic structures and calculating confidence scores, effectively suppressing octave errors, distinguishing stable periodic structures from noise disturbances, thereby generating a continuous and stable speech fundamental frequency trajectory.

This invention relates to a method for generating and segmenting multi-level pseudo-labels for the inner ear labyrinth based on prior spatial location and structure information, belonging to the field of medical image processing. The method proposes a technique for generating multi-level target structure pseudo-labels on the central osseous line based on prior information about the spatial location and structure of the inner ear labyrinth. This generates pseudo-labels comparable to those manually annotated by professional physicians, serving as the training and validation set for an automatic instance segmentation network with multi-level annotation. Leveraging existing semantic segmentation networks that have manually annotated a large number (68 cases) of single structures in the inner ear labyrinth, a small-sample (10 cases) initial model for multi-level segmentation of the inner ear labyrinth is achieved, enabling automatic segmentation of the horizontal semicircular canals, superior semicircular canals, posterior semicircular canals, vestibule, and cochlea within the inner ear labyrinth. Then, based on an active learning paradigm, the most valuable samples in the initial model are selected to update and optimize the initial multi-level segmentation model.

The present disclosure provides polynucleotides and nucleic acid vectors containing a GJB2 regulatory construct operably linked to a polynucleotide encoding a gap junction protein beta2 (Gjb2) protein (e.g., a wild-type human Gjb2 protein). These polynucleotides and vectors can be used to express Gjb2 in cells expressing GJB2, including cochlear supporting cells, and thus can be used to treat subjects suffering from or at risk of developing GJB2-related hearing loss.

This invention proposes a weighted fusion wind noise reduction method for helmets. The method includes: Step 1: Placing reference microphone 1 inside the helmet, slightly to the right of the chin; reference microphone 2 inside the helmet, at the level of the right ear; reference microphone 3 inside the helmet, at the level of the right temple; and an error microphone at the cochlea of ​​the right ear. The signals picked up by multiple reference microphones are weighted and fused into a single reference signal for feedforward active noise control. Step 2: The reference signal, after being trained by a fixed-coefficient feedforward control filter in Step 1, is superimposed with the feedback reference signal, which is iteratively updated in real time, to jointly act on the active noise control. This invention proposes a physical layout of reference microphones for helmet wind noise reduction and a weighted fusion wind noise reduction method for helmets. It achieves good noise reduction performance with low computational load, low hardware resource requirements, and strong practicality.

The application discloses a gene medicine for treating deafness-dystonia-optic neuropathy syndrome caused by TIMM8A gene defect and application. The medicine core is a modularly designed adeno-associated virus vector system which carries an expression cassette containing a tissue-specific promoter and a human TIMM8A treatment gene. The application realizes precise treatment through local minimally invasive injection according to different symptoms: AAV-Anc80L65-MYO15-TIMM8A is injected into the cochlea to treat sensorineural hearing loss; AAV2 / 4-Brn3b-TIMM8A is injected into the vitreous body of the eyeball to treat optic neuropathy; AAV9-hSyn-TIMM8A is injected into the central lateral ventricle to treat dystonia. Preclinical studies have confirmed that the strategy can efficiently express TIMM8A protein in the corresponding target cells, significantly repair hearing, visual and motor function defects, and correct mitochondrial dysfunction from the pathological mechanism.

An ear-wearable electronic device comprises a housing configured for deployment at least partially within an ear canal of a wearer, sound processing circuitry, and a vibratory transducer disposed in the housing and coupled to the sound processing circuitry. The vibratory transducer comprises an oscillator arrangement disposed in a sealed case. The vibratory transducer is configured to generate output signals in the form of audible sound transmissible via air conduction to an eardrum of the wearer and vibratory signals for stimulating a cochlea of the wearer via transcranial bone conduction.